Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Orders Flu Vaccine from Sinovac, Hualan; Approves Relenza

publication date: Sep 4, 2009

China has ordered 7.3 million doses of H1N1 flu vaccine from two domestic manufacturers: 3.3 million does from Sinovac (北京科兴生物制品有限公司) and 4 million doses from Hualan Biological Engineering Inc. Also, China granted emergency approval for Relenza (zanamivir), a GlaxoSmithKline drug that is both a prophylaxis and treatment for influenza A and B. Simcere (先声药业) owns the exclusive right to market Relenza in China. More details...

Stock Symbols: (NYSE Amex: SVA) (NYSE: GSK) (NYSE: SCR)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here